Education
About Us
Working with TipRanks
Follow Us
Genomma Lab Internacional SAB de CV Class B (DE:GEKA)
:GEKA
RESEARCH TOOLSreports
Earnings Data
Report Date
Jul 23, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: -12.15%
|Next Earnings Date:Jul 23, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong sales growth, improved margins, and record cash flow generation. Challenges persist in specific segments and markets, but overall performance exceeded expectations.Company Guidance
In the third quarter of 2024, Genomma Lab reported impressive financial performance, with sales increasing by 15.9% year-over-year, bolstered by strong performances in key markets such as Mexico, Brazil, Argentina, and the U.S. The company's gross margin improved by 184 basis points to 64.3%, while EBITDA expanded by 245 basis points, reaching 23.7%, driven by productivity initiatives and manufacturing efficiencies. Net income surged by 78.1%, and earnings per share (EPS) grew by 81.6%. Genomma's cash conversion cycle was reduced to 117 days, or 95 days when adjusted for inflationary accounting in Argentina. The company's cash flow generation reached a record high of MXN 2,404 million over the past 12 months, marking a 68.1% increase. Additionally, 73% of sales either maintained or gained market share, with 92% outpacing inflation. The company also highlighted a commitment to generating MXN 1,800 million in productivity savings, having completed 42% of this target by Q3 2024.Strong Sales Growth
Sales increased by 15.9% with notable performance in Mexico, Brazil, Argentina, and the U.S. Gross margin improved by 184 basis points, reaching 64.3%.
EBITDA and Net Income Surge
EBITDA expanded by 245 basis points to 23.7%. Net income surged by 78.1% and earnings per share grew by 81.6%.
Record High Cash Flow Generation
Cash flow generation over the past 12 months hit a record high of MXN 2,404 million, representing a 68.1% increase.
Operational Improvements
Significant progress in reducing the cash conversion cycle to 117 days, or 95 days when adjusted for inflationary accounting in Argentina.
Successful Market Share Gains
73% of sales maintained or gained market share with 92% of sales outpacing inflation.
U.S. Market Performance
Net sales in the U.S. increased by 12% in dollar terms and 25.8% in Mexican pesos, with a 440 basis point increase in EBITDA margin.
GMP Approval in Mexico
Health authorities in Mexico granted GMPs for pending forms at the San Cayetano plant.
Genomma Lab Internacional SAB de CV (DE:GEKA) Earnings, Revenues Date & History
DE:GEKA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:GEKA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2025 | €1.07 | €1.01 | -5.61% |
Feb 27, 2025 | €1.20 | €1.18 | -1.67% |
Oct 23, 2024 | €1.08 | €1.15 | +6.38% |
Jul 24, 2024 | €0.85 | €0.82 | -2.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Genomma Lab Internacional SAB de CV Class B (DE:GEKA) report earnings?
Genomma Lab Internacional SAB de CV Class B (DE:GEKA) is schdueled to report earning on Jul 23, 2025, TBA Not Confirmed.
What is Genomma Lab Internacional SAB de CV Class B (DE:GEKA) earnings time?
Genomma Lab Internacional SAB de CV Class B (DE:GEKA) earnings time is at Jul 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Genomma Lab Internacional SAB de CV Class B stock?
The P/E ratio of Genomma Lab Internacional SAB de CV is N/A.
What is DE:GEKA EPS forecast?
Currently, no data Available